

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wan, et al. 11 October 2007
Serial No.: 10/577,834 Group Art Unit No.: 1625
Filed: 1 May 2007 Examiner: C. Aulakh
For: MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


FILING OF A FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper.

Please note that WIPO publication WO 2000/006545 has a corresponding US publication (US 2003/073690) and two US Patents, of which the 2 US patents are cited on the enclosed PTO1449 Form, e.g., US 6,455,527 and US 6,262,066.

This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090